Last updated 12 days ago
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
810 patients around the world
Available in Argentina, United States, Spain, Brazil
Bristol-Myers Squibb
14Research sites
810Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Participant has documented diagnosis of MM and measurable disease, defined as any of the following.i) M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) orii) M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP) oriii) For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio.Participants received 1 to 3 prior lines of antimyeloma therapy.Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy.
- Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below:i) Subjects who progressed while being treated with, or within 60 days of last dose of bortezomib maintenance given once every 2 weeks or less are not excluded.For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity.Participant has had prior treatment with mezigdomide or pomalidomide.
Sites
Instituto Multidisciplinario de Oncología - CIC - Clínica Viedma, Río Negro.
Hospital Británico de Buenos Aires - CABA
Swiss Medical Center Barrio Parque - CABA
Hospital Privado de Córdoba
Clínica de Nefrología Urología y Enfermedades Cardiovasculares - Santa Fe
Sanatorio Chivilcoy
Hospital Mãe de Deus - Porto Alegre
Recruiting
Instituto Joinvilense de Hematologia e Oncologia (CEPEVILLE)
Recruiting
Hospital Amaral Carvalho
Recruiting
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
Recruiting
StudySuccessor-1
SponsorBristol-Myers Squibb
Study typeInterventional
Conditions
Multiple myeloma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05519085
